{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-024353","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2026-05-19T12:03:26+00:00","discovered_at":"2026-05-19T12:05:00.339181+00:00","generated_at":"2026-05-19T12:06:57.865962+00:00","sec_items":["1.01","2.02","2.03","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AIM ImmunoTech increases stockholder equity to $2.1M, extends note maturity to June 2027","bullets":["Stockholder equity rose to ~$2.1M as of March 31, 2026, from a deficit of ~$9.8M at Dec 31, 2025 (+$11.9M).","Entered Amendment #2 with Streeterville Capital, extending promissory note maturity to June 30, 2027; outstanding balance ~$1.68M.","Extension fee of $10,000 added to note balance; additional equity-generating funds raised since March 31.","CEO states amendment enhances capital allocation flexibility for pancreatic cancer program and other initiatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-024353","json":"https://secwatch.observer/filing/0001493152-26-024353.json","markdown":"https://secwatch.observer/filing/0001493152-26-024353.md","text":"https://secwatch.observer/filing/0001493152-26-024353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315226024353/0001493152-26-024353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315226024353/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T12:06:57.865962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8245637877f77127e75452900e85e95713c3d43d","claim":"AIM ImmunoTech Inc. amended loan of $1,682,676.16 with Streeterville Capital, LLC maturing June 30, 2027.","evidence_excerpt":"as a representation and warranty of the Company that, as of the date of the Amendment, the outstanding balance of the Note, following the application of the Extension Fee, was $1,682,676.16. The foregoing is only a summary of the material terms of the Amendment and does not purport to be a complete description of the rights and obligations of the parties thereunder.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226024353/0001493152-26-024353-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$1,682,676.16"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Maturity","value":"June 30, 2027"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"0f73bbd48c1f48a43e516979fbf9de566d2c09f9","claim":"AIM ImmunoTech Inc. amended Amendment #2 to Promissory Note with Streeterville Capital, LLC valued at extension fee in the amount of $10,000.00 (effective 2026-05-18).","evidence_excerpt":"On May 18, 2026, the Company and the Lender entered into Amendment #2 to Promissory Note (the “Amendment”), which amended the Note and further extended the maturity date of the Note until June 30, 2027. Pursuant to the Amendment, the Company agreed to pay the Lender an extension fee in the amount of $10,000.00 (the “Extension Fee”), which Extension Fee was added to the outstanding balance of the Note.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226024353/0001493152-26-024353-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Value","value":"extension fee in the amount of $10,000.00"},{"label":"Effective","value":"2026-05-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}